在震主导的帕金森病中,皮层-皮层连接受勒沃多巴的影响
B K Rurak1, J Tan1, J P Rodrigues2
1Discipline of Psychology, College of Science, Health, Engineering and Education, Western Australia, Australia; Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Western Australia, Australia.
Neurobiology of disease
|April 28, 2024
概括
多巴胺药物改变了帕金森病 (PD) 患者的大脑连接. 这项研究发现,改变了辅助运动区 (SMA) 与主要运动皮层 (M1) 的连接,与PD的静止的减少相关.
科学领域:
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
- 神经生理学 神经生理学
背景情况:
- 休息是帕金森病 (PD) 的主要运动症状.
- 补充运动区域 (SMA) 和主要运动皮层 (M1) 是由多巴胺调节的运动控制电路的关键组成部分.
- SMA和M1都与PD休息的病理生理学有关.
研究的目的:
- 为了研究多巴胺药物 (莱沃多巴) 对帕尔马病患者SMA-M1连接性的影响.
- 确定SMA-M1连接是否与PD静止的严重程度有关.
主要方法:
- 采用双部位的横磁刺激 (TMS) 来评估SMA-M1连接性.
- 患有PD的参与者被研究了Levodopa药物的开启和关闭.
- 休息时的震被用电肌图 (EMG) 和加速计量量化.
主要成果:
- 在PD患者中,SMA刺激抑制了PD患者的M1兴奋性 OFF levodopa.
- 通过SMA刺激,在使用levodopa的PD患者中促进了M1刺激性.
- 在服用药物时,增强的SMA-M1促进与静止的严重程度降低相关.
结论:
- 利沃多巴药物改变了帕金森病中SMA-M1功能连接.
- 通过多巴胺调节SMA-M1连接,为治疗PD静止提供了一个潜在的神经生理学标.
相关概念视频
Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Direct Motor Pathways
1.9K
The direct motor pathways, also known as the pyramidal tracts, are a group of neural pathways that originate in the brain and descend through the spinal cord. They control the voluntary movement of the body. There are two major direct motor pathways: the corticospinal and the corticobulbar tracts.
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
1.9K
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


